
Penumbra (PEN) Stock Forecast & Price Target
Penumbra (PEN) Analyst Ratings
Bulls say
Penumbra is positioned for attractive fundamental growth because its Thunderbolt FDA clearance on 6/11 makes it the only approved stroke CAVT device in the U.S., expanding its leadership in acute ischemic stroke with a first-of-its-kind platform that may improve clot removal speed and completeness. The company also benefits from a broad, under-penetrated addressable market, including a US vascular TAM of $2.7B, more than +1MM intervention patients, and a neuro/vascular portfolio that supports sustained double-digit revenue growth through product innovation. With OUS revenues at ~29% of 2024 and high-single-digit CAGR expected through 2030, Penumbra’s differentiated technology, premium pricing potential, and international expansion create a compelling long-term outlook.
Bears say
Penumbra is vulnerable because its acute ischemic stroke growth depends on a broad shift from stent retrievers to aspiration therapy, yet the evidence base remains device-agnostic and may not prove superior functional outcomes for its approach. It also faces entrenched competition from Medtronic, Stryker, Boston Scientific, Johnson & Johnson, and Terumo, whose greater scale and pricing power could pressure share and margins while continued innovation and regulatory approvals remain essential to growth. Although favorable U.S. reimbursement currently supports the business, any reimbursement deterioration, product launch missteps, supply chain disruption, litigation, or deferred procedures could quickly impair execution and valuation.
This aggregate rating is based on analysts' research of Penumbra and is not a guaranteed prediction by Public.com or investment advice.
Penumbra (PEN) Analyst Forecast & Price Prediction
Start investing in Penumbra (PEN)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Penumbra (PEN) Forecast
Penumbra (PEN) Analyst Forecast & Price Prediction
Start investing in Penumbra (PEN)
Order type
Buy in
Order amount
Est. shares
0 shares